ADAM17 and neoplasm: Furthermore, the growth of ADAM17‐deficient A549 tumor xenografts in NSG mice was significantly impaired compared to ADAM17‐expressing control A549 xenografts, as demonstrated by ~4‐fold and ~5‐fold reductions in final (day 21) tumor volumes and weights, respectively (Fig 6L–N).